Lilly’s Mounjaro gains first US cardiovascular risk reduction label for type 2 diabetes drug

Eli Lilly’s diabetes medication Mounjaro has received FDA approval for a new indication to reduce cardiovascular risk in high-risk adults with type 2 diabetes, marking a significant advancement in its clinical use and competitive positioning.

Eli Lilly has won a broader US label for Mounjaro, giving the blockbuster diabetes medicine a formal role in reducing the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with type 2 diabetes who are at high risk of those events. The change was set out in an FDA supplement approval letter signed on 27 August 2026 and announced by Lilly the following day. In the same regulatory action, the agency also cleared revised prescribing information stating that the 2.5mg dose may be used for ongoing glycaemic control and updated warnings on diabetic retinopathy complications in patients with a history of the condition. (accessdata.fda.gov)

The decision gives tirzepatide a different kind of standing in diabetes care: not only as a drug for blood sugar and weight, but as one with an explicit cardiovascular claim on its US label. Pharmacy Times said the move makes Mounjaro the first dual GIP and GLP-1 receptor agonist to gain that indication. Jennifer Goldman, a professor of pharmacy practice quoted by the publication, said: “This is bigger than another indication for another diabetes medication.” Forbes Health, meanwhile, quoted cardiologist Yu-Ming Ni describing the approval as a reminder of the drugs’ “wide-ranging effects including cardiovascular benefits”. (pharmacytimes.com)

What underpins the approval is SURPASS-CVOT, a study designed to answer a harder question than a standard placebo-controlled trial. Rather than compare tirzepatide with no active treatment, Lilly tested it against dulaglutide, sold as Trulicity, a medicine that already had an established cardiovascular benefit. Lilly said 13,299 participants were randomised 1:1 across 640 sites in 30 countries. Specialist coverage in TCTMD and Pharmacy Times added that the trial population consisted of adults with type 2 diabetes and established atherosclerotic cardiovascular disease, followed for a median of four years and more than four and a half years overall. (lilly.gcs-web.com)

That does not mean Mounjaro has proved itself decisively better for the heart than Trulicity. The 8% relative advantage cited in coverage of the trial points to a numerical edge, but the main study result met non-inferiority rather than superiority. A JAMA Cardiology analysis of SURPASS-CVOT said the primary comparison produced a hazard ratio of 0.92, with major cardiovascular events in 12.2% of patients on tirzepatide and 13.1% on dulaglutide; the superiority test did not reach statistical significance. Pharmacy Times drew the same distinction, arguing that the label supports cardiovascular benefit against an active comparator of known value, not a claim that tirzepatide has clearly surpassed it. (jamanetwork.com)

Even so, clinicians have reasons to see more than a bureaucratic label tidy-up. In a March 2026 post hoc paper, JAMA Cardiology reported lower rates for a broader six-part cardiorenal composite, including revascularisation, heart-failure admission and adverse kidney outcomes, with an absolute risk reduction of 3.7% versus dulaglutide and a number needed to treat of 27. The authors were careful about the limits: the trial only enrolled people already at high cardiovascular risk, so the results should not be assumed to apply to lower-risk patients. That caution matches the FDA wording, which confines the new indication to high-risk adults with type 2 diabetes. (jamanetwork.com)

Prescribers are also unlikely to be surprised by the tolerability profile. TCTMD, citing Lilly’s announcement, said the most commonly reported adverse events in SURPASS-CVOT were gastrointestinal, generally mild to moderate, and concentrated during dose escalation. The FDA letter adds another practical point for clinicians: warnings and precautions were revised for diabetic retinopathy complications in patients with a history of retinopathy. For a drug already used widely in diabetes care, those details may matter almost as much in clinic as the headline cardiovascular language. (tctmd.com)

The commercial backdrop makes the timing especially useful for Lilly. Managed Healthcare Executive reported that Mounjaro generated $18.6 billion in first-half 2026 sales, up 106% from a year earlier, while Zepbound, the same molecule sold for weight management, produced $9.09 billion, up 60%. The publication also said Mounjaro carries a wholesale acquisition cost of $1,112.16, with Lilly offering some commercially insured patients a $25 copay for a three-month supply and selling through a direct-to-consumer platform for $499 a month. David A. D’Alessio, a Duke University co-author of SURPASS-CVOT, said “mitigating cardiovascular risk is essential and can be overlooked.” (managedhealthcareexecutive.com)

The approval, however, does not leave Lilly alone in the cardiovascular incretin market. TCTMD noted that semaglutide already has FDA risk-reduction indications as Ozempic in adults with type 2 diabetes and established cardiovascular disease, and as Wegovy in adults without diabetes who have overweight or obesity alongside established cardiovascular disease. That means Lilly’s regulatory win is better read as a strengthening of tirzepatide’s competitive hand than the creation of an empty field. The more immediate effect is likely to be on prescribing conversations, reimbursement arguments and the drug’s status in patients whose diabetes and heart risk are treated together rather than separately. (tctmd.com)